WO1990014067A3 - Procedes de traitement de l'angoisse a l'aide de ligands de recepteur sigma - Google Patents

Procedes de traitement de l'angoisse a l'aide de ligands de recepteur sigma Download PDF

Info

Publication number
WO1990014067A3
WO1990014067A3 PCT/US1990/002398 US9002398W WO9014067A3 WO 1990014067 A3 WO1990014067 A3 WO 1990014067A3 US 9002398 W US9002398 W US 9002398W WO 9014067 A3 WO9014067 A3 WO 9014067A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
sigma receptor
receptor ligands
treating anxiety
anxiety
Prior art date
Application number
PCT/US1990/002398
Other languages
English (en)
Other versions
WO1990014067A2 (fr
Inventor
John F W Keana
Eckard Weber
Original Assignee
Oregon State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State filed Critical Oregon State
Priority to DE69011859T priority Critical patent/DE69011859T2/de
Priority to EP90908385A priority patent/EP0473671B1/fr
Publication of WO1990014067A2 publication Critical patent/WO1990014067A2/fr
Publication of WO1990014067A3 publication Critical patent/WO1990014067A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé de traitement ou de prophylaxie de l'angoisse chez un animal, consistant à administrer une quantité anxiolytique de guanidine à disubstitution N,N', ayant une affinité élevée envers le récepteur sigma.
PCT/US1990/002398 1989-05-02 1990-05-02 Procedes de traitement de l'angoisse a l'aide de ligands de recepteur sigma WO1990014067A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE69011859T DE69011859T2 (de) 1989-05-02 1990-05-02 Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.
EP90908385A EP0473671B1 (fr) 1989-05-02 1990-05-02 Utilisation de ligands des recepteurs sigma pour fabriquer un anxiolytique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34649489A 1989-05-02 1989-05-02
US346,494 1989-05-02

Publications (2)

Publication Number Publication Date
WO1990014067A2 WO1990014067A2 (fr) 1990-11-29
WO1990014067A3 true WO1990014067A3 (fr) 1991-04-04

Family

ID=23359655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/002398 WO1990014067A2 (fr) 1989-05-02 1990-05-02 Procedes de traitement de l'angoisse a l'aide de ligands de recepteur sigma

Country Status (9)

Country Link
EP (1) EP0473671B1 (fr)
JP (1) JPH05500798A (fr)
AT (1) ATE110265T1 (fr)
AU (1) AU642881B2 (fr)
CA (1) CA2054211A1 (fr)
DE (1) DE69011859T2 (fr)
DK (1) DK0473671T3 (fr)
ES (1) ES2057568T3 (fr)
WO (1) WO1990014067A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312840A (en) * 1986-07-10 1994-05-17 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education Substituted guanidines having high binding to the sigma receptor and the use thereof
US5478863A (en) * 1986-07-10 1995-12-26 State Of Oregon, Oregon Health Sciences University Of Oregon Substituted guanidines having high binding to the sigma receptor and the use thereof
US5262568A (en) * 1990-03-02 1993-11-16 State Of Oregon Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
EP0517852B1 (fr) 1990-03-02 2002-07-10 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of Guanidines tri et tetra substitues et leur utilisation en tant qu'antagonistes d'aminoacides excitateurs
EP0532642A1 (fr) * 1990-05-25 1993-03-24 STATE OF OREGON, acting through OREGON STATE BOARD OF HIGHER EDUCATION, acting for OREGON HEALTH SC. UNIV. AND UNIV. OF OREGON Guanidines substituees ayant un coefficient de liaison eleve avec le recepteur sigma et utilisation de ces substances
US5741661A (en) * 1991-02-08 1998-04-21 Cambridge Neuroscience, Inc. Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers
US5847006A (en) * 1991-02-08 1998-12-08 Cambridge Neuroscience, Inc. Therapeutic guanidines
EP0584088B1 (fr) * 1991-02-08 1999-10-27 Cambridge Neuroscience Research, Inc. Guanidines substituees et leurs derives utilises comme modulateurs de liberation de neurotransmetteurs et nouveau procede d'identification d'inhibiteurs de liberation de neurotransmetteurs
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
CN1188121C (zh) * 1993-05-27 2005-02-09 剑桥神经科学公司 治疗性取代的胍类
AU703138B2 (en) * 1993-11-22 1999-03-18 Cambridge Neuroscience, Inc. Therapeutic guanidines
EP0739200A4 (fr) * 1993-11-23 1997-12-17 Cambridge Neuroscience Inc Guanidines substituees a usage therapeutique
US7351743B1 (en) 1994-02-03 2008-04-01 Wyeth Therapeutic guanidines
US6787569B1 (en) 1994-02-03 2004-09-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
US6143791A (en) * 1994-02-03 2000-11-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
WO1995020950A1 (fr) 1994-02-03 1995-08-10 Cambridge Neuroscience, Inc. Guanidines therapeutiques
WO1995023132A1 (fr) * 1994-02-23 1995-08-31 Cambridge Neuroscience, Inc. Agents bloquants des canaux ioniques et leur procedes d'utilisation
US6875759B1 (en) 1999-07-21 2005-04-05 Kadmus Pharmaceuticals Substituted guanidines and the use thereof
EP1749824A1 (fr) 2005-08-03 2007-02-07 Neuro3D Derivés de la benzodiazepine, préparation et utlisations thérapeutiques
US9296697B2 (en) 2005-08-24 2016-03-29 Abbott Laboratories Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (fr) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2013292519B2 (en) * 2012-07-19 2017-12-07 Drexel University Sigma receptor ligands for modulating cellular protein homeostasis
US11117870B2 (en) 2017-11-01 2021-09-14 Drexel University Compounds, compositions, and methods for treating diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709094A (en) * 1986-07-10 1987-11-24 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Sigma brain receptor ligands and their use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709094A (en) * 1986-07-10 1987-11-24 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Sigma brain receptor ligands and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TINS, Volume 10, Number 1 page 37-40 (1988), SONDERS, M.S. et al. "Phenylcyclidine and psycotomimetic sigma opiates: recent insights into their biochemical and physiological sites of action". See entire document. *
TINS, Volume 10, Number 11 page 461-463 (1987), FILE, S.E., "The Search For Novel Anxiolytics". See page 461, column 1. *

Also Published As

Publication number Publication date
DK0473671T3 (da) 1994-09-19
JPH05500798A (ja) 1993-02-18
ATE110265T1 (de) 1994-09-15
EP0473671A4 (en) 1992-04-01
DE69011859D1 (de) 1994-09-29
CA2054211A1 (fr) 1990-11-03
WO1990014067A2 (fr) 1990-11-29
AU5728790A (en) 1990-12-18
EP0473671A1 (fr) 1992-03-11
AU642881B2 (en) 1993-11-04
ES2057568T3 (es) 1994-10-16
EP0473671B1 (fr) 1994-08-24
DE69011859T2 (de) 1994-12-15

Similar Documents

Publication Publication Date Title
WO1990014067A3 (fr) Procedes de traitement de l'angoisse a l'aide de ligands de recepteur sigma
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
MY104343A (en) Novel pyridizinamine deravatives
ATE163195T1 (de) Lösliche liganden für cd40
AU609664B1 (en) A method of treating premature ejaculation using sertraline
TW223029B (fr)
GR3024379T3 (en) Peptides with organo-protective activity, the process for preparing them and their use in therapy
GB9009106D0 (en) Processes and intermediates for synthetic antibody derivatives
FI910653A0 (fi) Synteettiset reseptorianalogit
MY106231A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones.
AU6006090A (en) A method of increasing adenosine excretion
DE69006911D1 (de) Verfahren zur Herstellung von 3,4-Dichloranilin.
IL117157A (en) Preparation of factor ix form biological sources
MY131024A (en) Immunostimulating 6-aryl-5, 6-dihydroimidazo [2,1-b] thiazole derivatives.
AU634003B2 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
PH24094A (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
WO1992018536A3 (fr) Procede de detection et de localisation de tissus comprenant des recepteurs de neurokinine 1
DE69205601D1 (de) Verfahren zur Herstellung von 3-Cyano-3,5,5-trimethylcyclohexanon.
DE68922507D1 (de) Verfahren zur Herstellung von beta-2',2'-Difluornukleosiden.
EP0421216A3 (en) Process for the preparation of 2,4, resp. 2,6 dihalo-aniline
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
EP0116628A4 (fr) 1-acyl-3-pyridylmethylguanidines et leur utilisation comme agents anti-hypertensifs.
DE68913995D1 (de) Zusammensetzung zur behandlung progressiver myopie.
DE3669159D1 (de) Triazinderivate, verfahren zur herstellung dieser derivate und herbizide, welche diese derivate als wirksame komponente enthalten.
DE59007022D1 (de) Verfahren zur kontinuierlichen Herstellung von Nylon 4,6.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2054211

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1990908385

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990908385

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1990908385

Country of ref document: EP